NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. (Decision date - January 2017).
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. (Decision date - January 2017).
DO NOT PRESCRIBE (DNP):
NICE TA714:treating Philadelphia-chromosome-positive acute
lymphoblastic leukaemia. (Terminated appraisal). (Decision date - August 2021).
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
